Scinai Immunotherapeutics Ltd.
SCNINasdaq
$0.25
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -88.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.3B
Enterprise Value
$2.3B
P/E
—
P/S
1779.6
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-0.3%
Dividend Yield
—
Revenue (TTM)
$1.3M
Net Income (TTM)
-$8.3M
Free Cash Flow (TTM)
-$6.1M
Gross Margin
-202.3%
Operating Margin
-575.3%
Net Margin
-633.6%
ROE
116.8%
ROIC
—
Debt / Equity
—
Net Cash
$7.5M
Return 1Y
-88.3%
Company profile
BiondVax Pharmaceuticals Ltd. focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- CEO
- Amir Reichman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- biondvax.com
Earnings
SCNI Q2 2023 Earnings
Period ends 2023-06-30
MetricActualYoY
Revenue——
Diluted EPS-$0.00↓ -25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $658,000.00 | $1.3M |
| Gross profit | — | — | — | -$580,000.00 | -$2.7M |
| Operating income | -$10.9M | -$11.1M | -$9.7M | -$8.6M | -$7.5M |
| Net income | -$8.2M | -$5.8M | -$6.5M | $4.8M | -$8.3M |
| Diluted EPS | -$0.02 | $0.01 | $0.00 | — | — |
| Operating cash flow | -$7.4M | -$7.3M | -$9.4M | -$6.3M | -$6.0M |
| Free cash flow | -$7.6M | -$8.1M | -$10.0M | -$6.3M | -$6.1M |
| Gross margin | — | — | — | -88.1% | -202.3% |
| Operating margin | — | — | — | -1312.8% | -575.3% |
| Net margin | — | — | — | 728.9% | -633.6% |
| Line item | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$2.6M | -$3.3M | -$3.2M | -$2.6M |
| Net income | -$2.5M | -$3.0M | -$3.5M | -$3.8M |
| Diluted EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| Operating cash flow | -$1.1M | -$3.7M | -$3.1M | -$2.9M |
| Free cash flow | -$1.6M | -$3.7M | -$3.1M | -$3.3M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
Company news
May 20, 2026
Apr 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | GERMAIN MARK | Award | 120,000,000 | $0.00 | $0.00 | filing |
| 2026-06-16 | Reichman Amir· Chief Executive Officer | Award | 400,000,000 | $0.00 | $0.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.